Datavault AI Inc. (NASDAQ: DVLT) has signed a nonbinding letter of intent to acquire a 19.9% equity interest in DataMEDS AI Inc. (NASDAQ: MEDS), as reported by DefenseWireNews. The proposed transaction would be executed in exchange for expanding an existing technology license between the two companies, allowing Datavault AI to retain ownership of its underlying intellectual property while potentially generating royalty revenue from the commercialization of the licensed technologies. The announcement matters because it outlines a capital-efficient path for Datavault AI to participate in the health care data economy without bearing the full cost of commercialization.
Under the terms of the proposed deal, DataMEDS would assume commercialization costs, and Datavault AI would have the right to designate one director to the DataMEDS board following closing. Datavault AI believes a fourth-quarter 2026 closing is achievable, subject to due diligence, definitive agreements and customary closing conditions. The letter of intent does not obligate either party to complete the transaction.
The proposed expanded license would build on DataMEDS’ existing PharmacyChain platform and EinsteinRx AI capabilities, incorporating Datavault AI Health technologies designed to support patient-controlled health data access, management, monetization and tokenization across pharmacy, laboratory, wearable and other health care environments. The initiative is part of broader efforts by DataMEDS to expand its health care technology capabilities through arrangements with several companies, including EOS Technology Holdings, Scilex Holding Company, HealthBridge Advisors and REBOOT Health AI.
By retaining intellectual property and taking an equity stake, Datavault AI could benefit from both royalty streams and potential appreciation in DataMEDS’ value if the expanded platform gains traction. The board seat would also give Datavault AI influence over strategic decisions at DataMEDS, aligning the two companies’ interests as they seek to scale tokenized health data solutions. For DataMEDS, the expanded license provides access to Datavault AI’s health data technologies, which are intended to give patients control over their health information and enable its monetization across various care settings. The company’s existing platforms, PharmacyChain and EinsteinRx AI, would be augmented by these capabilities, potentially strengthening its position in the competitive health care technology market.
Datavault AI, headquartered in Philadelphia, describes itself as a provider of AI-driven data experiences and monetization solutions for the Web 3.0 environment. Its cloud-based platform serves industries including biotech, fintech, health care and energy. The company’s Information Data Exchange enables digital twins and the licensing of name, image and likeness by attaching physical real-world objects to immutable metadata. More information about Datavault AI is available at https://dvlt.ai, and its latest news and updates can be found in its newsroom at https://ibn.fm/DVLT.
The full press release can be viewed at https://ibn.fm/Q8IGK. DefenseWireNews is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other communications services.
